ADVFN - Advanced Financial Network.
HOME» NYSE » R » RMD Stock Price » RMD Stock News

Resmed Share News

 Resmed Inc. Stock Price
RMD Stock Price
 Resmed Inc. Stock Chart
RMD Stock Chart
 Resmed Inc. Stock News
RMD Stock News
 Resmed Inc. Company Information
RMD Company Information
 Resmed Inc. Stock Trades
RMD Stock Trades

TIP SHEET: Invesco Health Fund Seeks Out-Of-Favor Stocks

By Peter Loftus Of DOW JONES NEWSWIRES Derek Taner is on the hunt for health-care stocks that are out of favor due to company stumbles, but with potential to bounce back strongly. Taner manages the $1.1 billion Invesco Global Health Care fund (GGHCX), whose year-to-date returns of 17.1% outpace the average return for health-care funds tracked by Morningstar, as well as the Standard & Poor's 500 Index. "Our sweet spot has been to try to focus on companies that for whatever reason have stubbed their toe," said the San Francisco-based Taner. "We pick a stock with the idea that 18 months or two years out, the problems are fixable. The company still generates lots of cash ...and at some point that'll come back into favor." One example he cites is Quest Diagnostics Inc. (DGX), which provides diagnostic and laboratory services. The stock's performance has trailed that of rival Laboratory Corp. of America Holdings (LH), partly because Quest's acquisitions in recent years haven't boosted earnings as much as Lab Corp.'s, Taner said. But he sees few other reasons to justify why Quest shares should trade at a discount to Lab Corp.'s--Quest trades at 13 times projected full-year earnings while Lab Corp has a 16 times multiple. He sees improved financial results in the second half of the year propelling Quest shares. Quest shares have bounced back from a trough in the mid-40s last summer, trading recently around $57.65. Taner also likes medical-equipment maker CareFusion Corp. (CFN). He said the business wasn't being managed as profitably as it could have been, but the company in February named former ResMed Inc. (RMD) chief executive Kieran Gallahue as its new CEO. Taner expects Gallahue to cut costs and take other steps to improve profitability. CareFusion shares have bounced back to around $28.57 in recent trading from a low of $20.63 in July. Not every holding in Taner's fund fits the profile of out-of-favor stock waiting to bounce back. He also likes Amarin Corp. (AMRN), which is developing the drug AMR101, designed to lower high triglycerides. High triglycerides are a risk factor for heart-related problems. Amarin's American depositary shares have skyrocketed to $18.77 in recent trading from as low as $2.02 in July thanks to the release of positive results of clinical trials of the drug. Taner thinks the drug can generate annual sales exceeding $2 billion if it's cleared by regulators. Taner has mostly avoided large pharmaceutical stocks because most are facing patent expirations for top-selling drugs, which will trigger sales-eroding generic competition. He does, however, like Teva Pharmaceutical Industries Ltd. (TEVA), the biggest stand-alone generic-drug maker. -Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com (TALK BACK: We invite readers to send us comments on this or other financial news topics. Please email us at TalkbackAmericas@dowjones.com. Readers should include their full names, work or home addresses and telephone numbers for verification purposes. We reserve the right to edit and publish your comments along with your name; we reserve the right not to publish reader comments. Talk Back comments can be found under the N/TLK code)

Stock News for Resmed (RMD)
DateTimeHeadline
09/06/201608:51:00New Study Shows Using Non-Invasive Ventilation Therapy to Treat...
09/06/201601:00:00ResMed Expands COPD Offering as New Data Reveals Benefits of...
09/06/201601:00:00ResMed erweitert COPD-Angebot: Neue Daten zeigen Vorteile einer...
09/06/201601:00:00ResMed élargit son offre de traitement de la BPCO, alors que...
08/17/201617:17:00ResMed Takes Fisher & Paykel to Court over Patents
08/17/201617:10:00ResMed Takes Fisher & Paykel to Court over Patents
08/17/201617:10:00ResMed Takes Fisher & Paykel to Court over Patents
08/15/201619:03:00Fisher & Paykel Files Patent Infringement Claim Against ResMed
07/28/201616:05:00ResMed Inc. Announces Results for the Fourth Quarter of Fiscal...
07/26/201603:14:00Australia Stocks End up Slightly as Key Inflation Data Looms
07/07/201616:05:00ResMed to Announce Fourth Quarter Fiscal Year 2016 Results
07/07/201607:40:00What Investors are Making of These Medical Appliances and Equipment...
06/28/201609:00:00ResMed Awarded Group Purchasing Contract with Premier
06/20/201609:00:00ResMed Statement on Brightree Executive Appointments
06/13/201609:00:00Kaiser Permanente Study: ResMed Digital Platform Drives CPAP...
05/22/201602:40:00Adaptive Servo-ventilation (ASV) Therapy Suggests Positive Cardiovascular...
05/16/201606:30:00ResMed Life Support Ventilators to Join World's Largest Remote...
05/13/201606:00:00International Trade Commission to Investigate Chinese Manufacturer...
04/26/201616:05:00ResMed Inc. Announces Results for the Third Quarter of Fiscal...
04/04/201616:05:00It's a New Day for HME Business Efficiency

Resmed and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad